Verano Holdings (VRNO) Non-Current Deferred Tax Liability (2021 - 2026)
Verano Holdings' (VRNO) quarterly Non-Current Deferred Tax Liability came in at $36.7 million in Q1 2026, down 49.73% year-on-year from $73.0 million in Q1 2025, and little changed on a QoQ basis from $36.6 million in Q4 2025.
Verano Holdings (VRNO) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $36.7 million in Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 49.73% year-over-year to $36.7 million in Q1 2026; TTM through Mar 2026 was $36.7 million, a 49.73% decrease from a year earlier, with the FY2025 full-year figure at $36.6 million, down 63.85% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $36.7 million, roughly flat from $36.6 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for VRNO reached as high as $259.3 million in Q2 2022 and fell as low as $2.7 million in Q1 2022.
- Historically, Non-Current Deferred Tax Liability has averaged $140.2 million across 5 years, with a median of $174.8 million in 2024.
- Across the five-year window, Non-Current Deferred Tax Liability jumped 26219.88% in 2022 and sank 63.85% in 2025, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $209.0 million in 2022, then decreased by 12.8% to $182.2 million in 2023, then tumbled by 44.38% to $101.4 million in 2024, then sank by 63.85% to $36.6 million in 2025, then grew by 0.11% to $36.7 million in 2026.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $36.7 million in Q1 2026, $36.6 million in Q4 2025, and $71.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.69 Mn |
| Mar 31, 2026 | 36.69 Mn |
| Dec 31, 2025 | 36.64 Mn |
| Dec 31, 2025 | 36.64 Mn |
| Sep 30, 2025 | 71.02 Mn |
| Sep 30, 2025 | 71.02 Mn |
| Jun 30, 2025 | 72.37 Mn |
| Jun 30, 2025 | 72.37 Mn |
| Mar 31, 2025 | 72.98 Mn |
| Mar 31, 2025 | 72.98 Mn |
| Dec 31, 2024 | 101.36 Mn |
| Dec 31, 2024 | 101.36 Mn |
| Sep 30, 2024 | 168.16 Mn |
| Sep 30, 2024 | 168.16 Mn |
| Jun 30, 2024 | 174.79 Mn |
| Jun 30, 2024 | 174.79 Mn |
| Mar 31, 2024 | 180.25 Mn |
| Mar 31, 2024 | 180.25 Mn |
| Dec 31, 2023 | 182.22 Mn |
| Dec 31, 2023 | 182.22 Mn |